



ALLA MAGNIFICA RETTRICE  
DELL'UNIVERSITA' DEGLI STUDI DI MILANO

COD. ID: 6986

Il sottoscritto chiede di essere ammesso a partecipare alla selezione pubblica, per titoli ed esami, per il conferimento di un assegno di ricerca presso il Dipartimento di Dipartimento di Scienze Biomediche e Cliniche

Responsabile scientifico: Prof. Perrotta Cristiana

**Fateme Naghavihosseini**

## CURRICULUM VITAE

### INFORMAZIONI PERSONALI

Cognome	Naghavihosseini
Nome	Fateme

### OCCUPAZIONE ATTUALE

Incarico	Struttura
Research Assistant	Influenza and other Respiratory Viruses - Pasteur Institute of Iran

### ISTRUZIONE E FORMAZIONE

Titolo	Corso di studi	Università	anno conseguimento titolo
Laurea Magistrale o equivalente	Pharm.D	Faculty of Pharmacy, Isfahan University of Medical Sciences, Iran	2020
Specializzazione	Doctor of pharmacy		
Dottorato Di Ricerca			
Master			
Diploma Di Specializzazione Medica			
Diploma Di Specializzazione Europea			
Altro			

### ISCRIZIONE AD ORDINI PROFESSIONALI

Data iscrizione	Ordine	Città
-----------------	--------	-------



--	--	--

## LINGUE STRANIERE CONOSCIUTE

lingue	livello di conoscenza
English	C1 (Overall 7.5 IELTS)
Persian	Native

## PREMI, RICONOSCIMENTI E BORSE DI STUDIO

anno	Descrizione premio
2022	Certificate of cooperation in the research projects of the influenza and other respiratory diseases department during the corona pandemic in Pasteur Institute of Iran
2018	Silver Medal in Health management section at "10th Scientific Olympiad of Medical Students in Iran" held in Iran University of Medical Sciences, August 2018, Tehran, Iran.
2013- 2020	Awarded the Iranian Governmental fund for studying Pharm.D

## ATTIVITÀ DI FORMAZIONE O DI RICERCA

**RESEARCH ASSISTANT at Pasteur Institute of Iran (JUNE 2020 - PRESENT):** Official working experience (full-time) at Influenza and Respiratory Viruses Department. I was member of COVID-19 Pandemic Team and actively participated in a comprehensive COVID-19 research project. My responsibilities included collecting samples from suspected patients and ensuring proper storage of these samples, RNA extraction of SARS-CoV-2 from patient samples, Performing RT-PCR to detect and report analysis. Also, conducting research projects including molecular and cellular tests (PCR, RT-PCR, VNT, ELISA, Flowcytometry, VNT) regarding influenza diagnosis and treatment. Risk assessment responsibility. Quality control of primary cell culture room and standards of facilities such as incubator, BSL2 and BSL3 equipment and stations.

**Member of Student Research Committee at MOTAMED Breast cancer center, Tehran, Iran (2019-2020):** Participating in breast cancer research projects and clinical trial, focusing primarily on data collection, patient research, and data analysis. My work has included two significant systematic reviews on biomarkers in breast cancer, specifically on EGFR2 (Epidermal Growth Factor Receptor 2) and CTC (Circulating Tumor Cells). These reviews aimed to identify and analyze the potential of these biomarkers in the prognosis and treatment of breast cancer.

## ATTIVITÀ PROGETTUALE

Anno	Progetto
2022	"H5 influenza pseudovirus production and evaluation by virus neutralization test"



2020	"Cloning and Expression of Interferon Beta-1a in CHO cell line"
2019	"The Prognostic Value of Circulating Tumor Cells in Primary Breast Cancer Prior to any Systematic Therapy"

## TITOLARITÀ DI BREVETTI

<b>Brevetto</b>

## CONGRESSI, CONVEGNI E SEMINARI

Data	Titolo	Sede
July 2022	"Construction of influenza pseudovirus and its use in evaluating the neutralizing effect of antibodies produced with H5 vaccines" 8th Iranian Congress of Virology,	<a href="https://congress.isv.org.ir/">https://congress.isv.org.ir/</a>
September 2019	"Cloning and Expression of Interferon Beta-1a in CHO cell line" presented in the 3rd International & 11th National Biotechnology Congress of Iran	<a href="https://www.en.symposia.ir/NBC111">https://www.en.symposia.ir/NBC111</a>
2018	Poster presentation "A rare presentation of acute myelogenous leukemia; case report of vaginal uterine myeloid sarcoma from Iran" at the 18th Asian conference on clinical pharmacy	<a href="https://civilica.com/l/9159/">https://civilica.com/l/9159/</a>
2016	Lecture on importance of finding new biomarkers for ER positive and ER negative breast cancer patients	<a href="https://financialtribune.com/articles/people/41544/cancer-congress-in-mashhad">https://financialtribune.com/articles/people/41544/cancer-congress-in-mashhad</a>

## PUBBLICAZIONI

<b>Libri</b>
[titolo, città, editore, anno...]



[titolo, città, editore, anno...]

[titolo, città, editore, anno...]

## Articoli su riviste

"Evaluating human epidermal growth factor receptor 2 roles in the efficacy of Tamoxifen treatment in breast cancer, a systematic review" published in Pharmacological reports 2021.  
<https://doi.org/10.1007/s43440-021-00237-z>

A policy brief: Rationing of total hip and total knee replacement in Iran, An inseparable part of reducing unnecessary costs" published by Eastern Mediterranean Health Journal, November 2020, DOI:  
<https://doi.org/10.26719/emhj.20.109>

"Optimization of Anti-CXCL10 Nanobody Expression Using Response Surface Methodology and Evaluation of its Anti-metastatic Effect on Breast Cancer cells" published in the International Journal of Peptide Research and Therapeutics, October 2019, DOI: <https://doi.org/10.1007/s10989-019-09941-0>

" The Prognostic Value of Circulating Tumor Cells in Primary Breast Cancer Prior to any Systematic Therapy: A Systematic Review" published in the Current Stem Cell Research & Therapy journal, 2019, Pages 519 - 529. DOI: <http://dx.doi.org/10.2174/1574888X14666190306103759>

"MED1 may explain the interaction between receptor tyrosine kinases and ERα66 in the complicated network of Tamoxifen resistance" published in the European Journal of Pharmacology, June 2017. DOI: <https://doi.org/10.1016/j.ejphar.2017.03.026>

## Atti di convegni

[titolo, struttura, città, anno]

[titolo, struttura, città, anno]

[titolo, struttura, città, anno]

## ALTRE INFORMAZIONI

I want to express my interest and assume that I am well-prepared for this fellowship due to my background and expertise. As a pharm.D. graduate, I may not proceeded the routine way of pharmacists, however I am deeply passionate about scientific research and advancement which led me to immerse myself in the stimulating and cutting-edge biomedical field including Milan university. My thesis in university was about Interferon Beta1-a production in CHO cell lines which is one of the basic treatment for multiple sclerosis and after that as a research assistant at the Pasteur Institute of Iran, I have acquired comprehensive hands-on experience in RNA sequencing and various molecular techniques as well as my abilities and skills in cell culture (2D and 3D), transfection methods, cloning, gel electrophoresis, plasmid extraction, SDS-PAGE, immunoblot, PCR, cDNA synthesis, genome sequencing (NGS), virus RNA replication, VNT, MTT and confocal and fluorescent microscopy analysis. I have made significant contributions to multiple breast cancer research projects, particularly in the areas of data collection, patient research, and data analysis. These experiences have endowed me with the necessary skills to excel in the proposed research activities. I am highly enthusiastic about the prospect of contributing to this fellowship project under the supervision of Prof. Perrotta Cristiana to explore more about new therapeutic strategies with my background in pharmaceutical science inorder to better understand the mechanism of muscular diseases and utilize the potential to improve medicinal strategies.



# UNIVERSITÀ DEGLI STUDI DI MILANO

Le dichiarazioni rese nel presente curriculum sono da ritenersi rilasciate ai sensi degli artt. 46 e 47 del DPR n. 445/2000.

Il presente curriculum, non contiene dati sensibili e dati giudiziari di cui all'art. 4, comma 1, lettere d) ed e) del D.Lgs. 30.6.2003 n. 196.

**RICORDIAMO** che i curricula **SARANNO RESI PUBBLICI sul sito di Ateneo** e pertanto si prega di non inserire dati sensibili e personali. Il presente modello è già precostruito per soddisfare la necessità di pubblicazione senza dati sensibili.

Si prega pertanto di **NON FIRMARE** il presente modello.

Luogo e data: \_\_\_\_\_Tehran\_\_\_\_\_, \_\_\_\_11/11/2024\_\_\_\_\_